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Abstract
Background: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive
(HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision
oncology. The aim of this study was to identify novel epigenetic biomarkers associated to trastuzumab resistance in
HER2+ BC patients.
Methods: We performed a genome-wide DNA methylation (450K array) and a transcriptomic analysis (RNA-Seq)
comparing trastuzumab-sensitive (SK) and trastuzumab-resistant (SKTR) HER2+ human breast cancer cell models.
The methylation and expression levels of candidate genes were validated by bisulfite pyrosequencing and qRT-PCR,
respectively. Functional assays were conducted in the SK and SKTR models by gene silencing and overexpression.
Methylation analysis in 24 HER2+ human BC samples with complete response or non-response to trastuzumab-
based treatment was conducted by bisulfite pyrosequencing.
Results: Epigenomic and transcriptomic analysis revealed the consistent hypermethylation and downregulation of
TGFBI, CXCL2, and SLC38A1 genes in association with trastuzumab resistance. The DNA methylation and expression
levels of these genes were validated in both sensitive and resistant models analyzed. Of the genes, TGFBI presented
the highest hypermethylation-associated silencing both at the transcriptional and protein level. Ectopic expression
of TGFBI in the SKTR model suggest an increased sensitivity to trastuzumab treatment. In primary tumors, TGFBI
hypermethylation was significantly associated with trastuzumab resistance in HER2+ breast cancer patients.
Conclusions: Our results suggest for the first time an association between the epigenetic silencing of TGFBI by
DNA methylation and trastuzumab resistance in HER2+ cell models. These results provide the basis for further
clinical studies to validate the hypermethylation of TGFBI promoter as a biomarker of trastuzumab resistance in
HER2+ breast cancer patients.
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Background
Breast cancer (BC) is the most common cancer in women
worldwide and the leading cause of cancer deaths for
women [1]. Approximately 15–20% of patients with this
tumor overexpress the human epidermal growth factor re-
ceptor 2 (HER2) protein [2]. HER2 can activate down-
stream signaling cascades that induce cell proliferation
through the Ras-mitogen-activated protein kinase
(MAPK) pathway and inhibit cell death through the phos-
phatidylinositol 3′-kinase (PI3K)/protein kinase B (Akt)/
mammalian target of the rapamycin (mTOR) pathway [3,
4]. Characterizing HER2 as a proto-oncogene, a poor
prognostic marker, and eventually as a therapeutic target
has dramatically changed BC classification, risk assess-
ment, and treatment [5]. The development of powerful
targeted therapies directed specifically at HER2 has im-
proved the survival of patients with both early-stage and
metastatic BC.
Trastuzumab (Herceptin®; Genentech, Inc., South San
Francisco, CA, USA) is a humanized monoclonal antibody
that selectively binds with high affinity to the extracellular
domain of human HER2 protein and was the first targeted
drug approved for treating HER2+ BC [6]. Although there
are currently other anti-HER2 agents available, trastuzu-
mab remains the gold standard for treating this subtype of
BC. Despite the clinical benefits trastuzumab treatment in
HER2+ BC brings, a large percentage of patients display
primary or acquired resistance to the drug. In the last few
years, several studies have focused on identifying the mo-
lecular mechanisms of trastuzumab resistance, such as ab-
errant activation of downstream signaling pathways [7] or
the HER2 carboxyl-terminal fragments (CTF), also known
as p95HER2, which are frequently found in HER2-
expressing BC cell lines and tumors [8]. Despite these ef-
forts, the complete picture of the molecular mechanisms
triggering trastuzumab resistance in BC remains unclear.
Therefore, clarifying these mechanisms and identifying
new resistance biomarkers is essential in the advance to-
wards precision oncology in BC and the quest for new
treatment options for those patients who do not respond
to trastuzumab therapy.
DNA methylation is the most well-known epigenetic
modification in humans and has been implicated in
regulating the expression of a great variety of critical
genes in cancer [9]. For this reason, DNA methylation
status has emerged as one of the most promising epi-
genetic biomarkers for several types of cancer, includ-
ing BC [10]. These epigenetic markers can be useful in
detecting tumors earlier or identifying patients with an
increased risk of cancer, as well as evaluating disease
progression or predicting the response to anticancer
drugs [11]. In the last few years, some significant genes
that are inactivated by promoter methylation in BC have
been identified, including BRCA1 [12] and RASSF1A [13].
However, the analysis of hypermethylated genes in associ-
ation with trastuzumab resistance is still a largely unex-
plored field that holds great potential.
The aim of this study was to evaluate the implication
DNA methylation has in trastuzumab resistance and to
identify epigenetically regulated genes with potential
clinical value as biomarkers for trastuzumab resistance
in HER2+ BC patients. To this purpose, we employed an
integrative approach with genome-wide DNA methyla-
tion (450K array) and a transcriptomic analysis (RNA-
Seq) in trastuzumab-sensitive and trastuzumab-resistant
cell line models (SK and SKTR). In vitro results were
validated in a cohort of 24 HER2+ tumor samples from
patients experiencing both sensitivity and resistance to
trastuzumab-based neoadjuvant therapy settings. Here,
we determine epigenetic inactivation of the TGFBI gene
by promoter CpG island hypermethylation, which are
CpG-rich regions of DNA that are often associated with
the transcription start sites of genes, with possible impli-
cations for trastuzumab-resistant BC pathways [14]. The
hypermethylation of TGFBI also suggest its potential
clinical usefulness as a biomarker for trastuzumab resist-
ance in HER2+ BC patients.
Methods
Cell culture
SKBr3 (SK) and AU565 (AU) HER2+ breast carcinoma
cells were obtained from Eucellbank (University of Barce-
lona, Spain) [15] and the American Type Culture Collec-
tion (ATCC, Rockville, MD, USA). SKBr3 and AU565 cells
were routinely grown in McCoy’s (Gibco) and Dulbecco’s
modified Eagle’s medium (DMEM; Gibco), respectively,
and supplemented with 10% FBS (HyClone Laboratories),
1% L-glutamine (Gibco), 1% sodium pyruvate (Gibco), and
100U/mL penicillin/streptomycin (HyClone Laboratories).
Cell lines were kept at 37 °C and 5% CO2 atmosphere.
Long-term trastuzumab-resistant SK cells (SKTR) and
AU565 cells (AUTR) had been previously developed in our
laboratory [16, 17]. Resistance was confirmed with cell via-
bility assays. The trastuzumab-resistant SKTR and AUTR
cells were maintained in 2 μM of trastuzumab, i.e., a con-
centration in which parental cells were not viable.
Patients and tissue samples
TGFBI promoter methylation levels were retrospectively
evaluated in tumor samples from 24 patients diagnosed
with HER2+ BC at the Dr. Josep Trueta University Hos-
pital, Girona (Spain) between 2007 and 2015. The pa-
tients were selected from the hospital’s pharmacy database.
The selection criterion included patients with early or lo-
cally advanced HER2+ BC who had received neoadjuvant
treatment with trastuzumab and chemotherapy. Twenty
patients had no response or partial response and 4 patients
had complete response to trastuzumab plus chemotherapy.
Palomeras et al. Breast Cancer Research           (2019) 21:79 Page 2 of 16
For all patients, hematoxylin and eosin (H&E)-stained slides
from formalin-fixed paraffin-embedded (FFPE) tumor
blocks were examined to determine the representative areas
of the invasive tumor. Estrogen receptor (ER), progesterone
receptor (PR), and HER2 expression had been previously
analyzed in the tumors using immunohistochemistry (IHC)
. For each patient, clinical and histopathological features
were obtained: age, stage (TNM classification [18]), histo-
logical grade (Bloom-Richardson grading system), meno-
pause status, type of surgery, and relapse.
5-Aza-2′-deoxycytidine treatment
Epigenetic signatures are characterized by a very dy-
namic nature, where DNA methylation has often been
shown as a reversible mechanism of transcriptional con-
trol by inhibition of enzymes such as the DNA methyl-
transferases [19]. We performed reactivation treatments
using the demethylating agent, 5-aza-2′-deoxycytidine
(5-aza-dC, Sigma-Aldrich, St Louis, MO) at 3 μM and
5 μM of 5-aza-dC for 72 h. The medium was changed
every day to promote DNA demethylation.
DNA and RNA isolation procedures
Genomic DNA extraction from cell lines or formalin-fixed
paraffin-embedded (FFPE) core biopsies (10 μm) and tis-
sue sections (5 μm) using a QIAamp DNA Mini Kit and
Deparaffinization Solution with a QIAamp DNA FFPE
Tissue Kit (Qiagen, Hilden, Germany), respectively, were
carried out following the manufacturer’s instructions. For
the RT-PCR experiments, cells were washed with PBS and
then suspended in 1mL of Qiazol (Qiagen Hilden,
Germany) was added. Total RNA was isolated using a
GeneJET RNA Purification Kit (Thermo Fisher Scientific)
following the instructions provided by the manufacturer.
All DNA and RNA samples were quantified using a Nano-
Drop 2000 Spectrophotometer (Thermo Fisher Scientific).
DNA was bisulfite-modified using an EZ DNA
Methylation-Gold Kit (Zymo Research) in accordance
with the manufacturer’s recommendations.
DNA methylation array
Genome-wide DNA methylation analysis was performed
using an Illumina 450K DNA methylation microarray
(Infinium HumanMethylation450 BeadChip) as previously
described [20]. This technique is an epigenomic approach
that allows analyzing the methylation profile of the human
genome. Bisulfite-converted DNA from SK and SKTR
models were used to hybridized on an Illumina Infinium
HumanMethylation450 (450K) BeadChip array, following
the Illumina Infinium HD Methylation protocol. Sex chro-
mosomes were excluded from the analysis because they
usually represent a high source of variation in DNA
methylation levels [21]. Data was deposited into the NCBI
Gene Omnibus, accession number: GSE123754.
RNA sequencing
DNA methylation is an epigenetic mechanism that usually
affects CpG islands and promoters regulating the expres-
sion of the genes. For this reason, a transcriptomic ana-
lysis by RNA-Seq was performed. Library construction
was performed using an Illumina TruSeq Stranded mRNA
Sample Preparation Kit (CAT. No. RS-122-2101, RS-122-
2102). Following the transfer of the flow cell to an Illu-
mina HiSeq instrument, a 101-cycle paired-end sequence
run was performed using the HiSeq SBS Kit v4 sequencing
reagents (FC-401-4002). A detailed description of the ana-
lysis is provided in the Additional file 1. Sequencing data
have been posted in the Gene Expression Omnibus (GEO)
database under accession number GSE114575.
Bisulfite pyrosequencing
To validate the results obtained from the arrays, bisulfite
pyrosequencing analyses were performed. The primers
for the PCR amplification and sequencing were designed
with the PyroMark assay design software version
2.0.01.15. DNA-bs was amplified by PCR under standard
conditions with biotinylated primers (see Additional file 1:
Table S1) to convert the PCR product into single-
stranded DNA templates. We used a Vacuum Prep Tool
(Biotage, Sweden) to prepare single-stranded PCR prod-
ucts following the manufacturer’s instructions. The PCR
products were observed in 2% agarose gels before pyro-
sequencing. Reactions were performed in a PyroMark
Q96 System version 2.0.6 (Qiagen, Hilden, Germany)
using appropriate reagents and protocols. The methyla-
tion value was obtained from the average of the CpG di-
nucleotides included in the sequences analyzed using a
Pyro Q-CpG 1.0.9 (Qiagen, Hilden, Germany).
Methylation-specific PCR (MSP)
DNA methylation was also validated using the methylation-
specific PCR (MSP) using a set of primers designed by the
Methyl Primer Express program for each gene analyzed.
For each sample, two PCR reactions were produced using
the same DNA template: one reaction with methylated
primers (M: methylated) and the other with unmethylated
primers (U: unmethylated). Commercial methylated human
male genomic DNA (CpGenome Universal Methylated
DNA, Millipore) was used as a methylated positive control
(IVD), and DNA from normal lymphocytes (NL) as a posi-
tive control for unmethylated alleles. Primer sequences can
be found in Additional file 1: Table S2.
Gene expression analysis (qRT-PCR)
To confirm the differential regulation of TGFBI, CXCL2
and SLC38A1 observed in SK and SKTR models used
gold standard methodologies for gene expression such
as quantitative real-time PCR. Total RNA was reverse-
transcribed into cDNA using a High Capacity cDNA
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Archive Kit (Applied Biosystems). Gene expression levels
of selected genes were assessed using a LightCycler 480
Real-time PCR System (Roche) with a LightCycler 480
SYBR Green I Master (Roche). Primers are depicted in
Additional file 1: Table S3. RT-PCR analyses were per-
formed at least four times, and each gene was run in
triplicate. GAPDH was used as an endogenous control
to enable normalization.
Short hairpin interference and ectopic expression assays
For the TGFBI long-term knockdown, two different
ShRNAs were specifically designed against TGFBI
mRNA (NM_000358) in two different loci, by consid-
ering a 19-base target sequence and inserted in the
pLVX-shRNA2 vector (Clontech). For stable overex-
pression, the cDNA sequence of TGFBI was amplified
from SKWT cDNA and cloned into the pLVX-IRES-
tdTomato vector (Clontech). This construction (wild
type) was then used as a template to create its mutated
version following a PCR-based strategy. Mutations were
performed in the RGD domain and the NKDIL (amino
acids 354–358), YH18 (amino acids 563–580), and EPDIM
(amino acids 617–621) motif in the second and fourth
FAS-1 domains [22]. Lentiviral production was performed
using the protocol described in Additional file 1. After len-
tiviral transduction, ZsGreen1-positive or tdTomato-
positive cells were sorted by flow cytometry.
Cell viability assays
Cell viability was determined using a 3-(4, 5-dimethyl-2-
thiazolyl)-2, 5-diphenyl-2 h-tetrazolium bromide (MTT)
assay. Briefly, cells were plated in their growth medium
in 96-well plates at a cell density of 1.5 × 103 cells per
well. After 24 h, the growth medium was removed, and,
100 μL of fresh medium containing the corresponding
concentration of trastuzumab was added to each well for
5 days. Cell viability was measured using the standard
colorimetric MTT assay as previously described [16].
Using the multi-well plate reader Benchmark Plus (Bio-
Rad), absorbance was determined to be 570 nm. Data
presented are from three separate wells per assay, and
the assay was performed at least three times.
Western blot analysis
We previously demonstrated that different activation
patterns of some HER receptors and their downstream
signaling proteins are associated with the molecular
mechanisms of acquired trastuzumab resistance (SK
and SKTR) [16]. For this reason, a panel of the different
proteins were analyzed in our models using Western
blot analysis. The parental (SK and AU) and resistant
(SKTR and AUTR) models were synchronized by star-
vation in serum-deprived medium (0.5% FBS) for 24 h.
Cells were lysed in ice-cold lysis buffer (Cell Signaling
Technology, Inc.) with 100 μg/mL phenylmethylsulfo-
nylfluoride (PMSF). Protein concentration was deter-
mined with Lowry (DC Protein Assay, Bio-Rad). Equal
amounts of protein were heated in LDS Sample Buffer
with Sample Reducing Agent (Invitrogen) for 10 min at
70 °C, separated on SDS-PAGE and transferred to
nitrocellulose membranes. Protein was detected using
primary antibodies (Additional file 1: Table S5). Sec-
ondary antibodies, α-tubulin and β-actin, conjugated to
horseradish peroxidase were used. The immune com-
plexes were detected using a chemiluminescent HRP
substrate [SuperSignal™ West Femto Maximum Sensi-
tivity Substrate (Thermo Scientific™ Inc.) or Immobilon
Western HRP Substrate (Millipore Sigma)] and in a
Bio-Rad ChemiDoc™ MP Imaging System. Western blot
analyses were repeated at least three times and repre-
sentative results are shown.
Statistical analysis
Data were analyzed with Student’s t test when two groups
were being compared or with one-way analysis of variance
(ANOVA) followed by Tukey’s honest significant differ-
ence (HSD) post hoc test or Tamhane’s T2 post hoc test
for multiple comparisons. The non-parametric Kruskal-
Wallis test was used when data did not follow normal dis-
tribution. When two groups were being compared, the
data were analyzed with the Mann-Whitney U tests for
non-normally independent variables; otherwise, the
Kruskal-Wallis test was used for more than two groups. In
the patient cohort, we analyzed the TGFBI promoter
methylation status and its association with the clinical-
histopathological characteristics. Patient data were sum-
marized as median (first quartile-third quartile) for con-
tinuous variables, and frequencies and percentages for
categorical variables. The potential association between
clinical-histopathological characteristics and levels of
TGFBI methylation (low ≤ 20%, high ≥ 20%) or differences
in TGFBI methylation before and after treatment were an-
alyzed using the Mann-Whitney U and Kruskal-Wallis
tests for continuous variables and the chi-square or Fisher
exact tests, as appropriate, for categorical variables. The
correlation between variables was observed using Spear-
man’s rho coefficient. Characteristic (ROC) curves were
used to assess the predictive capacity of the TGFBI
marker. ROC curve analysis was performed using Med-
Calc software Version 18.11.3. The Hosmer-Lemeshow
test and calibration plot was assessed with MedCalc and
STATA software. Levels of significance were set at p <
0.05 and are represented by asterisks, as follows: p < 0.05
(denoted as *), p < 0.01 (denoted as **), and p < 0.001 (de-
noted as ***). The statistical analysis was performed using
the IBM SPSS software (Version 21.0; SPSS Inc.)
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Results
Genome-wide DNA methylation analysis in trastuzumab-
sensitive (SK) and trastuzumab-resistant (SKTR) breast
cancer models
The Infinium HumanMethylation 450 BeadChip (450k
array) is a validated tool for carrying out epigenomic
projects because it allows the methylation status of ap-
proximately 450,000 CpGs located throughout the hu-
man genome to be detected [20]. Our group recently
employed this approach in previous studies aimed at
identifying genes regulated by DNA methylation for clin-
ical applications such as biomarkers [23, 24]. Therefore,
we took advantage of the 450K array methodology to
characterize the DNA methylation profile associated
with trastuzumab resistance in BC, and compared a
trastuzumab-sensitive (SK) and trastuzumab-resistant
(SKTR) BC models (Fig. 1a). The global analysis of the
DNA methylation (β values) corresponding to the CpG
sites with p value < 0.01 (469,927 CpGs) showed differ-
ences in the scatter plot (Fig. 1b) between SK and SKTR
models (r2 = 0.93) and revealed 27,314 differentially
methylated CpGs (Δβ ≥ 0.20) between both models. In
particular, the number of CpGs that gained (red triangle
in scatter plot) and lost (green triangle in scatter plot) a
methylation level ≥ 0.20 in SKTR with respect to SK was
14,845 and 12,469, respectively.
Therefore, we focused our study on analyzing the methy-
lation levels of the CpG sites located at the regulatory re-
gions corresponding to 89,168 CpGs and 13,508 genes. The
supervised hierarchical clustering of the most variable
CpGs from promoters and islands (Δβ ≥ 0.20) showed a
methylation pattern that clearly discriminated between the
SK and SKTR models (Fig. 1c). Next, we used more strin-
gent criteria to determine the most differentially methylated
CpGs in the promoters and islands, considering in SKTR
the CpGs with a methylation level (β) in SK < 0.20 and in
SKTR > 0.60 as hypermethylated, and in SKTR the CpGs
with a methylation level (β) in SKTR < 0.20 and in SK >
0.60 as hypomethylated. This analysis revealed 184 differen-
tially methylated CpGs corresponding to 152 genes which,
according to a Gene Ontology analysis (GO), were signifi-
cantly associated (FDR < 0.05) with several biological pro-
cesses related to cancer, such as cell adhesion pathways
(GO:0007155), regulation of transcription (GO:0006355),
development (GO:0007275), and control of apoptosis (GO:
0043065) (Fig. 1d). To verify whether the methylation ob-
served in these genes had an impact on their transcriptional
expression or not, we performed a transcriptomic analysis
with RNA-Seq comparing the SK and SKTR models and
obtained 1995 overexpressed and 3191 downregulated
genes in SKTR displaying a fold change ≥ 1.5 over the SK
model. Then, we correlated the genes differentially methyl-
ated at the promoter and island with those differentially
expressed between SK and SKTR (Fig. 1e). We identified 31
hypermethylated and downregulated genes and no gene
hypomethylated and overexpressed in SKTR with respect
to the SK model (Table 1). From this list of 31 genes, we se-
lected three genes: TGFBI (transforming growth factor beta
induced), CXCL2 (C-X-C motif chemokine ligand 2), and
SLC38A1 (Solute carrier Family 38 Member 1) for further
analysis. TGFBI, CXCL2, and SLC38A1 were selected be-
cause of the high number of differentially methylated CpGs
(≥ 3 CpG sites) they presented and their previous implica-
tions in BC [25–27].
Epigenetic silencing of TGFBI, CXCL2, and SLC38A1 in
trastuzumab-resistant cells (SKTR)
First, we analyzed the DNA methylation of the selected
genes by bisulfite pyrosequencing, which is a technique
that allows single genes to be analyzed on a single CpG
level [28]. We observed significantly higher methylation
levels for the three genes in SKTR relative to the SK
(Fig. 2a; p < 0.05 for TGFBI and SLC38A1; p < 0.01 for
CXCL2). Like the previous transcriptomic analysis with
RNA-Seq, the SKTR model also showed a significant re-
duction in the transcript expression levels of TGFBI,
CXCL2, and SLC38A1 (p < 0.05) when compared to the
SK cells analyzed by qRT-PCR (Fig. 2b). Interestingly,
TGFBI was the gene that showed the greatest decrease
(fold change = 6.7) in transcriptional levels in the SKTR
model. Similar results were obtained by methylation-
specific polymerase chain reaction (MSP) analysis (a very
specific and sensitive method [29]) that showed higher
methylation in SKTR with respect to the SK cells for all
the genes evaluated (Fig. 2d). These results confirmed that
hypermethylation of the three selected genes at the pro-
moter and CpG island in SKTR cells is associated with re-
duce transcriptional levels.
In this sense, after treating the SKTR model with the
demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) at
3 μM and 5 μM (Fig. 2c), the transcriptional levels of
TGFBI, CXCL2, and SLC38A1 were significantly restored
(p < 0.05), indicating that methylation is an epigenetic
mechanism that has a functional role in the transcrip-
tional control of the three genes in question. Importantly,
this epigenetic silencing by DNA methylation observed
was also confirmed at the protein level in two (TGFBI and
CXCL2) of the three selected genes (Fig. 2e), showing a re-
duction of the protein levels in SKTR with respect to SK
cells that was significantly restored in the hypermethylated
SKTR model after the treatment with 5-aza-dC 3 μM and
5 μM. The change observed in the protein levels after the
5-aza-dC treatment was especially drastic in TGFBI gene,
where the absence of protein expression induced by the
promoter hypermethylation in SKTR was completely re-
covered after the in vitro demethylation.
Taken together, these results suggest that TGFBI, an
extracellular matrix (ECM) protein whose secretion is
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induced by transforming growth factor-β (TGF-β), is the
most epigenetically regulated gene of the three selected.
Therefore, to verify that the results obtained for these
genes were not specific to the SK and SKTR models, we
extended their epigenetic analyses to other trastuzumab-
sensitive (AU) and trastuzumab-resistant (AUTR) hu-
man BC cell models (Fig. 2f and Additional file 2: Figure
S1). Likewise, only TGFBI gene showed a high correl-
ation between methylation, expression, and protein
levels in the AUTR model. With MSP, we observed that
hypermethylation of TGFBI in AUTR (compared to AU)
was associated with a significant decrease (p < 0.05) in the
transcriptional and protein levels of the gene. Importantly,
the transcriptional and protein levels of TGFBI gene were
both restored in the hypermethylated AUTR model after
the treatment with 5-aza-dC 3 μM and 5 μM. These re-
sults confirm that the epigenetic silencing of TGFBI by
DNA methylation is associated to trastuzumab resistance
in human BC cells.
The role of TGFBI expression in trastuzumab resistance
cells (SKTR)
We have shown that TGFBI promoter hypermethylation






Fig. 1 Analysis of the DNA methylation profile associated to trastuzumab resistance in breast cancer cell lines. a Schematic flow chart used to
identify differentially methylated genes associated to trastuzumab resistance after comparing the sensitive (SK) and resistant (SKTR) to
trastuzumab human breast cancer cell lines. b Scatter plot representing DNA methylation normalized levels (β values) of SK and SKTR cell lines.
Red and green triangles indicate the CpGs that gained and lost, respectively, a methylation level ≥ 0.20 in SKTR with respect to SK cells. c
Supervised hierarchical clustering of the most variable CpGs (Δβ ≥ 0.20) from island and promoter regions between the SK and SKTR cell lines. d
Summary of gene ontology (GO) analysis of the biological process categories for the 152 differentially methylated genes at CpG island and
promoter levels between the SK and SKTR cell lines. e Venn diagram showing the differentially methylated and differentially expressed genes
(obtained by RNA-Seq) between the SK and SKTR cell lines. The name of the 31 hypermethylated and downregulated genes in SKTR is indicated
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Table 1 Thirty-one differentially methylated and differentially expressed genes between the SK and SKTR models
TargetID Chr Position Gene name Gene region SK SKTR SKTR vs SK
cg08757148 1 24513722 IL28RA;IL28RA;IL28RA 1stExon;1stExon;1stExon 0.11 0.67 0.56
cg03470088 1 24513939 IL28RA;IL28RA;IL28RA TSS200;TSS200;TSS200 0.05 0.79 0.75
cg26558485 1 47489282 CYP4X1;CYP4X1 1stExon;5′UTR 0.14 0.69 0.54
cg06816106 2 29033352 SPDYA;SPDYA TSS1500;TSS1500 0.18 0.64 0.46
cg14798656 2 97760745 FAHD2B TSS200 0.17 0.62 0.45
cg25999267 3 39424992 SLC25A38;SLC25A38 1stExon;5′UTR 0.19 0.75 0.56
cg17264618 3 40429014 ENTPD3 5′UTR 0.14 0.61 0.46
cg09363539 3 124931746 SLC12A8 TSS200 0.01 0.82 0.81





cg20841906 3 160822911 B3GALNT1;B3GALNT1;
B3GALNT1;B3GALNT1
;B3GALNT1
5′UTR;5′UTR;5′UTR;5′UTR;TSS1500 0.06 0.70 0.64
cg20986370 4 57976171 IGFBP7 1stExon 0.19 0.69 0.49
cg19031658 4 74964856 CXCL2;CXCL2 1stExon;5′UTR 0.05 0.89 0.85
cg22847221 4 74964920 CXCL2;CXCL2 1stExon;5′UTR 0.13 0.61 0.48
cg00630212 4 74965135 CXCL2 TSS200 0.16 0.65 0.49
cg18804985 4 74965226 CXCL2 TSS1500 0.18 0.96 0.78
cg01429321 5 121413797 LOX;LOX 5′UTR;1stExon 0.10 0.62 0.52
cg21034676 5 135364552 TGFBI TSS200 0.11 0.61 0.51
cg14120129 5 135364575 TGFBI TSS200 0.06 0.61 0.55
cg09873933 5 135364580 TGFBI TSS200 0.09 0.63 0.54
cg07151644 6 31649089 LY6G5C TSS1500 0.16 0.60 0.44
cg07753583 7 150020206 LRRC61;ACTR3C;LRRC61 TSS200;5′UTR;TSS200 0.17 0.86 0.69
cg10348193 7 150020240 LRRC61;ACTR3C;LRRC61 TSS200;5′UTR;TSS200 0.15 0.97 0.82
cg11026333 7 150020269 LRRC61;ACTR3C;LRRC61 TSS200;5′UTR;TSS200 0.06 0.98 0.92
cg01270001 7 150020401 LRRC61;ACTR3C;LRRC61;LRRC61;LRRC61 1stExon;5′UTR;5′UTR;5′UTR;1stExon 0.13 0.94 0.81
cg22893248 7 150020751 ACTR3C;ACTR3C;LRRC61;LRRC61 1stExon;5′UTR;5′UTR;5′UTR 0.19 0.73 0.54
cg09327770 12 46663270 SLC38A1;SLC38A1 TSS200;TSS200 0.02 0.83 0.81
cg20463033 12 46663274 SLC38A1;SLC38A1 TSS200;TSS200 0.01 0.77 0.76
cg24795297 12 46663281 SLC38A1;SLC38A1 TSS200;TSS200 0.07 0.77 0.71
cg03859162 13 99404887 SLC15A1;SLC15A1 1stExon;5′UTR 0.12 0.66 0.55
cg03485262 14 92980031 RIN3 TSS200 0.04 0.72 0.68
cg08114373 14 92980204 RIN3;RIN3 5′UTR;1stExon 0.17 0.61 0.44





cg01549404 16 55358636 IRX6;IRX6 5′UTR;1stExon 0.11 0.61 0.50
cg01568244 16 67218584 KIAA0895L;EXOC3L TSS1500;Body 0.14 0.82 0.69
cg01666600 17 21279561 KCNJ12 TSS200 0.05 0.70 0.65
cg03928539 17 21279613 KCNJ12 TSS200 0.08 0.62 0.54
cg01637175 17 21281507 KCNJ12 5′UTR 0.08 0.78 0.70
cg11804833 17 40575289 PTRF;PTRF 1stExon;5′UTR 0.08 0.62 0.54
cg06093379 17 44896080 WNT3;WNT3 5′UTR;1stExon 0.01 0.83 0.82
cg24441185 18 9708096 RAB31 TSS200 0.06 0.92 0.86
cg17289202 18 56530789 ZNF532 5′UTR 0.13 0.80 0.67
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transcript and protein levels in two trastuzumab-
resistant models when compared to the corresponding
sensitive models. Therefore, we next examined the func-
tional contribution of epigenetic inactivation of the
TGFBI gene to trastuzumab resistance. We depleted the
endogenous TGFBI gene expression in the SK model by
stable transfection with two different short hairpin
RNAs (shTGFBI A and shTGFBI B). We also rescued
the TGFBI expression in the TGFBI-hypermethylated
and the downregulated SKTR models by stable transfec-
tion with a plasmid encoding the full-length TGFBI
cDNA (TGFBI).
TGFBI is an extracellular matrix (ECM) protein and
plays a role in mediating cell adhesion to the ECM, cell
proliferation, adhesion, migration, and differentiation
through interacting with collagen, fibronectin, laminin,
and several integrins [30–32]. These integrin-binding
properties of TGFBI have been related to different
integrin-binding motifs located in fasciclin-1 domains,
including NKDIL, YH18, and EPDIM as well as an Arg-
Gly-Asp (RGD) domain [22]. For this reason, we became
interested in determining whether this interaction be-
tween TGFBI with the ECM and integrins could be in-
volved in the trastuzumab resistance in our models.
With this objective in mind, we also expressed a mu-
tated form of TGFBI with four different altered integrin
binding motifs (NKDIL, YH18, EPDIM, and RGD), af-
fecting cellular adhesion through the integrin interac-
tions [22]. The transfection and validation protocols
were the same as for the overexpression vector.
Despite its known function in cell adhesion and
integrin-mediated signaling, we did not observe mor-
phological changes after depletion, overexpression, or
mutagenesis of TGFBI (Fig. 3a). The efficiency of the
transfection was assessed by measuring the TGFBI gene
expression using quantitative RT-PCR and Western blot-
ting (Fig. 3b). A significant change in its levels was de-
tected both after depletion and overexpression. Upon
TGFBI transfection, we analyzed the resistance or sensi-
tivity to trastuzumab in comparison to the parental and
empty vector-transfected cells through an MTT assay
over 5 days (Fig. 3c; Additional file 3: Figure S2). In the
SK model, we observed that TGFBI depletion did not
affect the trastuzumab response (Fig. 3c, upper panel).
In contrast, overexpression of TGFBI in SKTR led to a
significantly higher sensitivity at a trastuzumab concen-
tration of 10 μM compared to the resistant empty vector
cell line (Mock: p = 0.020) and the SKTR model (p =
0.004) (Fig. 3c, middle panel). The TGFBI mutated form
(TGFBImut) showed the same response to trastuzumab
treatment as the mock vector did, suggesting that
TGFBI-mediated trastuzumab sensitivity requires the
NKDIL, YH, EPDIM, and RGD binding motifs (Fig. 3c,
lower panel).
Therefore, we examined HER family protein receptors
and their downstream proteins related to PI3K/AKT and
MAPK/ERK1/2 pathways for changes after TGFBI deple-
tion, overexpression, and mutation (Fig. 3d). Consistent
with the results of the trastuzumab cell viability, TGFBI
depletion in SK cells showed no apparent changes in ei-
ther total protein or activation levels for any of the pro-
teins examined. Unlike TGFBI depletion, overexpression
of TGFBI and TGFBImut in the SKTR model produced
changes in the activation levels of some of the HER recep-
tors and downstream signaling proteins in comparison
with the mock control vector. In particular, overexpression
of either wild type TGFBI or its mutated form resulted in
a significant increase in the activation levels of HER1
(pHER1), HER2 (pHER2), and AKT (pAKT) compared to
the SKTR model (Mock) that contains hypermethylated
TGFBI without change in total levels of the respective
proteins. Hence, TGFBI overexpression and its mutated
form allow the trastuzumab-resistant model to adopt
similar activation levels for HER1, HER2, and AKT as the
trastuzumab-sensitive cells do.
These data suggest that selective overexpression of
TGFBI in the SKTR model (hypermethylated for TGFBI)
induces an increased sensitivity to trastuzumab and the
activation of HER1 and HER2 receptors and the AKT
downstream protein. Furthermore, the mutated domains
from the second and fourth FAS-1 regions of TGFBI are
involved in its response to trastuzumab treatment, but
not in its activation or interaction with HER2 down-
stream proteins. In summary, the SKTR model with an
overexpression of TGFBI presents a behavior similar to
the SK model.
Table 1 Thirty-one differentially methylated and differentially expressed genes between the SK and SKTR models (Continued)
TargetID Chr Position Gene name Gene region SK SKTR SKTR vs SK
cg22932336 19 4535070 PLIN5 5′UTR 0.10 0.88 0.78
cg04532834 19 4535188 PLIN5;PLIN5 1stExon;5′UTR 0.17 0.64 0.46
cg02505409 19 8429160 ANGPTL4;ANGPTL4
;ANGPTL4;ANGPTL4
5′UTR;1stExon;5′UTR;1stExon 0.16 0.79 0.63
cg06837791 19 8429491 ANGPTL4;ANGPTL4 1stExon;1stExon 0.17 0.61 0.44
cg12831261 21 45078437 RRP1B;HSF2BP TSS1500;5′UTR 0.01 0.93 0.92
*Italics denotes the three final genes selected for further analysis






Fig. 2 DNA methylation-associated silencing of selected genes comparing the trastuzumab-resistant and trastuzumab-sensitive cell line. a DNA
methylation levels of TGFBI, CXCL2, and SLC38A1 in SK and SKTR cell lines by bisulfite pyrosequencing and b methylation-specific polymerase
chain reaction (MSP) analysis. c Expression levels of TGFBI, CXCL2, and SLC38A1 in the unmethylated (SK) and methylated (SKTR) cell lines
determined by qRT-PCR. d Restored expression of selected genes (TGFBI, CXCL2, and SLC38A1) after DNA demethylating agent 5-aza-2′-
deoxycytidine (5-aza-dC) in the SKTR methylated cell line by qRT-PCR. e Protein expression of all selected genes (TGFBI, CXCL2, and SLC38A1) in SK
and SKTR cells before and after 5-aza-dC treatment by Western blot. f Analysis in AU and AUTR cell lines of TGFBI methylation by MSP (top) and
(middle) its transcriptional (qRT-PCR) and (bottom) protein levels (Western blot) before and after 5-aza-dC treatment. In MSP, the presence of
visible polymerase chain reaction products in lanes marked U indicates unmethylated sequences; the presence of products in lanes marked M
indicates methylated sequences. In vitro methylated DNA (IVD) was used as a positive control for methylated sequences. DNA from normal
lymphocytes (NL) was used as a negative control for methylated sequences. Results shown are representative of those obtained from three
independent experiments, and b-actin was used as a control. Values from pyrosequencing and qRT-PCR were determined from triplicates and are
expressed as the mean ± SEM. Significance of Mann-Whitney U test, **p < 0.01; *p < 0.05
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TGFBI hypermethylation in trastuzumab-resistant HER2+
breast cancer patients
Given the previous in vitro results obtained, we wanted to
determine whether the presence of the TGFBI promoter
CpG island hypermethylation-associated to trastuzumab
resistance also occurring in BC patients. Therefore, we
evaluated TGFBI gene methylation in human tumors from
24 HER2+ early BC patients as a preliminary study. As
with our sensitive and resistant models, we analyzed
TGFBI methylation by bisulfite pyrosequencing in pre-
treatment samples from patients who were complete re-
sponders and non-responders to trastuzumab-based ther-
apy (Fig. 4a). With the non-responder patients, we also
evaluated TGFBI methylation after treatment (post-treat-
ment samples), i.e., as we did in our SKTR model. For the
non-response patients, we obtained paired samples (pre-
treatment and post-treatment samples) from 10 patients,
pre-treatment samples only from 3 patients, and post-
treatment samples only from 7 patients. For the patients





Fig. 3 Impact of TGFBI expression in trastuzumab-resistant cells. a Representative bright-field microscopy images of TGFBI depletion (Scramble,
ShTGFBI A, and ShTGFBI B), overexpression (Mock and TGFBI), and mutagenesis (TGFBImut) in SK and SKTR cells. b Expression analysis by qRT-PCR
and Western blot showing the in vitro stable depletion of TGFBI in SK cells (left) and overexpression or mutagenesis of TGFBI in SKTR cells (right).
Values of qRT-PCR were determined from triplicates and are expressed as the mean ± SEM. c Cell viability determined by MTT assays upon the
use of increasing concentrations of trastuzumab (10−6 to 10 μM) for 5 days. (Upper) The TGFBI depletion in SK did not affect cell viability upon
trastuzumab treatment. (Middle) The TGFBI overexpression in SKTR cells (TGFBI) give rise to a major sensitivity to trastuzumab at 10 μM. (Bottom)
The TGFBI mutagenesis in SKTR cells (TGFBImut) did not affect cell viability after trastuzumab treatment. Results are expressed as percentage of
surviving cells after drug treatment (mean ± SEM). One-way ANOVA using a Tukey HSD post hoc test, **p < 0.01; *p < 0.05 indicate levels of
statistical significance. d HER family receptors and their downstream proteins related to PI3K/AKT and MAPK/ERK1/2 pathway characterization in
TGFBI-depletion SK cells and TGFBI-overexpression SKTR cells. Western blot showing an enhanced of phosphorylation levels of HER1, HER2, and
AKT upon overexpression and mutagenesis of TGFBI in SKTR cells. TGFBI depletion did not produce any change in the HER receptors and their
related downstream proteins. Results shown are representative of those obtained from 3 independent experiments and β-actin was used as
a control
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samples were evaluated. The limited number of samples
obtained was, in part, due to the exhaustion of the sample
during diagnostic procedures and the poor preservation of
the DNA in the paraffin tissue (FFPE) blocks.
Our results showed similar pre-treatment TGFBI methy-
lation levels (p= 0.651) in the patients with complete re-
sponse to trastuzumab (6.45% ± 1.90) and in the non-
responders (6.08% ± 1.51; Fig. 4b). These results indicate
that the TGFBImethylation levels of the pre-treatment sam-
ples are not associated with the absence of response to tras-
tuzumab. In contrast, the non-responsive patients showed
significantly higher (p= 0.001) methylation levels of TGFBI
in tumors following treatment with trastuzumab (30.26% ±
3.52) than before starting the therapy (6.08% ± 1.51), sug-
gesting that acquired resistance to trastuzumab is associated
with increased methylation levels of TGFBI. In particular,
when considering the non-responsive patients with pre- and
post-treatment paired samples, we observed a significant
(p < 0.001) TGFBI promoter hypermethylation after trastu-
zumab (8 out of 10 = 80%) compared to the pre-treatment
samples, indicating that the increase in TGFBI methylation
levels is associated with trastuzumab resistance (Fig. 4c). Im-
portantly, the ROC curve analysis with an AUC of 0.95 (p <
0.0001; 95% CI 0.803 to 0.996) allowed us to clearly differen-
tiate the methylation levels of TGFBI between the pre- and
post-treatment samples of the non-responsive patients. This
result suggests that TGFBI could be a potential biomarker
for monitoring trastuzumab response during HER2+ BC pa-
tients’ treatment (Fig. 4d). In addition, the Hosmer-
Lemeshow test (chi-square = 89,606; p = 0.3456) suggests
that the methylation of TGFBI has a certain ability to pre-
dict the resistance to trastuzumab when compared with
an ideal model (Additional file 4: Figure S3). On the other
hand, no significant association between TGFBI methyla-
tion levels before and after treatment and the clinical-




Fig. 4 TGFBI promoter hypermethylation in HER2+ breast cancer patients with sensitivity and resistance to trastuzumab. a Schematic
representation of selected patient samples. TGFBI methylation levels were evaluated in tumor samples of 24 HER2+ breast cancer samples. From
this cohort, after trastuzumab plus chemotherapy in neoadjuvant regimen, 20 patients developed partial or no response and 4 patients presented
complete treatment response. Of the 20 patients with non-response, 10 patients had pre-treatment and post-treatment samples, 3 patients with
pre-treatment only samples, and 7 with post-treatment only samples (Top). The 4 patients with complete response to treatment only had pre-
treatment samples (Bottom). b TGFBI methylation of 3 consecutive CpG sites in the 5′-end promoter CpG island in HER2+ breast cancer treated
with trastuzumab analyzed by bisulfite pyrosequencing. The central solid line indicates the median and the limits of the vertical lines show the
upper and lower percentiles. c TGFBI methylation of 3 consecutive CpG sites in the 5′-end promoter CpG island in resistant patients with paired
pre- and post-treatment samples analyzed by bisulfite pyrosequencing. d Diagnostic accuracy of TGFBI hypermethylation for resistant HER2+
breast cancer samples. ROC analysis was applied to the TGFBI methylation levels analyzed by pyrosequencing for trastuzumab-resistant samples
(pre- and post-treatment samples). Area under the curve (AUC) was 0.9502 (p < 0.0001). TGFBI showed great potential for monitoring trastuzumab
response in HER2+ breast cancer patients. Significance of Mann-Whitney U test is indicated as ***p < 0.001; **p < 0.01
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Discussion
HER2 is overexpressed in 20–30% of BC and is associ-
ated with aggressive phenotype and poor prognosis. Des-
pite the initial good response to the treatment, a large
portion of patients present de novo or acquired treat-
ment resistance. Currently, HER2 detection is the only
validated biomarker for predicting the benefit of anti-
HER2 therapies [33]. While different cellular and mo-
lecular mechanisms involved in trastuzumab resistance
have been described, none of them are used to detect,
predict, or monitor BC treatment in a clinical routine [7,
8, 34]. Thus, there is great interest in finding potential
biomarkers able to detect, predict, or monitor trastuzu-
mab response which, in turn, would allow us to stratify
patients and save costs and toxicities for those who do
not respond to treatment.
Epigenetic biomarker studies are focused on analyzing
the methylation changes in the promoter regions of candi-
date genes in specific tumor types for the implication in
gene silencing [9, 34]. In general, this gene repression re-
sults in an adaptive advantage for the cells, allowing a
more aggressive and invasive phenotype to be adopted.
After analyzing the promoter methylation profile of long-
term trastuzumab-sensitive and trastuzumab-resistant
models developed in our laboratory [16, 17], three differ-
ent methylated genes (TGFBI, CXCL2, and SLC38A1) im-
plicated in cancer were identified and subsequently
validated using different methylation and expression ap-
proaches. Additionally, the selected genes were validated
in two other long-term trastuzumab-sensitive (AU) and
trastuzumab-resistant (AUTR) human HER2+ BC cell
lines developed by our group [17]. Although both cell
lines analyzed derive from the same patient and have simi-
lar genetic and transcriptomic profiles, they have some
differences in transcriptional levels [35]. Moreover, SKBr3
and AU565 have been described as having distinct re-
sponses to drug treatment depending on culture condi-
tions [36]. From all the genes selected,TGFBI (also known
as Big-H3 or keratoepithelin) was the only one with a con-
sistent methylation, expression, and protein pattern in
both resistant models. This epigenetic silencing of the
TGFBI gene observed was in line with previous studies of
other cancers [37, 38].
As explained before, TGFBI encodes a 68-kDa secretory
protein induced by transforming growth factor-β (TGF-β)
in human adenocarcinoma cells as well as other human
cell types [39]. According to the bibliography, TGFBI pro-
tein is composed by 683 amino acids containing a
secretory signal (SP) in the N-terminal cysteine-rich do-
main (CRD), and four fasciclin-1 domains (FAS1-1, FAS1-
2, FAS1-3, and FAS1-4), which contain several known
integrin-binding motifs including NKDIL, YH18, and
EPDIM as well as an Arg-Gly-Asp (RGD) domain [22].
TGFBI has been reported to function as an ECM protein
to mediate cell adhesion and migration through interact-
ing with collagen, fibronectin, and laminin and several
integrins including α1β1, α3β1, αvβ3, and αvβ5 [30–32].
While TGFBI has been reported to be involved in tumori-
genesis, its role is not clear. In this paper, we have linked
the promoter DNA methylation-associated silencing of
TGFBI with a possible tumor suppressor function in
trastuzumab-resistant models. Several previous reports
have indicated that TGFBI plays the role of a tumor sup-
pressor gene in various cancers such as lung, breast, and
ovarian [25, 40–42]. However, in other cancers, such as
colon or pancreas, TGFBI has been described as having a
Table 2 Clinical and pathological characteristics in HER2-







Age 10 −0.383* 0.275*1
Menopause 0.151*2
Premenopausal 5 32.13 (24.58–35.86)
Postmenopausal 5 14.58 (−0.68–25.77)
ER 0.089*2
Negative 2 2.85 (−3.57–9.28)
Positive 8 28.50 (19.58–34.00)
HER2 status –
FISH 0 –
IHC+ 10 25.18 (9.28–32.13)
Histological grade –
Grade 1–2 10 25.18 (9.28–32.13)
Grade 3 0 –
Clinical stage 0.804*3
IIB 2 16.15 (−3.57–25.86)
IIIA 2 19.58 (14.58–24.58)
IIIB 6 28.50 (9.28–32.13)
Pathological response –
No response 1 9.28
Partial response 9 25.77 (14.58–32.13)
Percentage of tumor shrinkage** 10 0.029 0.957*1
Miller & Payne 1.000*2
G2 1 0.68
G3 2 22.57 (9.28–35.86)
G4 7 25.77 (19.58–31.68)
Type of surgery 0.267*2
Lumpectomy 2 10.51 (−3.57–24.58)
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tumor-promoting function [43–46]. These opposing ef-
fects of TGFBI suggest that its expression and function
are dependent on cell type [22].
TGFBI promotes cell adhesion by interacting with
different integrins, which, in turn, has been shown to
play an important role in tumor progression in humans.
TGFBI’s inhibition of invasive capacity correlates with a
previous analysis by our group, which revealed a greater
invasive capacity for SKTR compared to the SK [16].
To determine if TGFBI has a potential role in trastuzu-
mab resistance, different functional studies were carried
out. Our results show that TGFBI overexpression in
SKTR significantly sensitizes the cells to the treatment
and activates some HER2 downstream protein pathways
(pAKT, pHER1, and pHER2), adopting a similar pattern
to SK. In contrast, TGFBI knockdown in TGFBI en-
dogenous expressed in the SK cells did not produce any
effect. A direct interaction between the HER2 receptor
and different integrins has been described in multiple
reports [47, 48]. Moreover, different integrins have been
related to trastuzumab resistance such as β1 or α6β4
[49, 50]. Therefore, TGFBI mutated vector was per-
formed to investigate the role of the RGD motif and
the three integrin-binding motifs NKDIL, EPDIM, and
YH18 in trastuzumab response [22]. Like TGFBI over-
expression, the TGFBI mutated form induced the acti-
vation of different HER2 downstream proteins, but
there were no differences in trastuzumab treatment re-
sponse. Therefore, it is likely that the four mutated do-
mains of TGFBI are required for its function in
trastuzumab response, which is consistent with other
studies that described the involvement of FAS1 or RGD
motifs in tumor angiogenesis and tumor growth inhib-
ition, as well as in promoting apoptosis [31, 51–53].
Moreover, it has also been described that TGFBI is in-
volved in mesothelioma progression through the AKT/
mTOR pathway which could be related to the HER2
pathway changes observed in TGFBI overexpression
and mutagenesis [54]. In summary, this study suggests
that TGFBI expression may promote the effectiveness
of trastuzumab treatment.
The methylation of TGFBI showed certain capacity to
predict the resistance to trastuzumab according to the
Hosmer-Lemeshow test; however, these results should
be interpreted with caution because the number of
grouped patients was small. Although more in vitro
functional analysis are necessary to elucidate the TGFBI
role in trastuzumab resistance, we suggest some hypo-
thetical situations taking into account all TGFBI action
mechanisms. It has been described that TGFBI could in-
hibit cell adhesion to various ECM proteins inhibiting
cell proliferation and invasion in neuroblastoma [55].
Moreover, cell adhesion to ECM has been consistently
reported as one of the mechanisms used by tumor cells
to resist chemotherapy [56]. These observations are in
correlation with previous studies by our group, where it
is exposed that our SKTR model presented a high sig-
nificant adhesion capacity to bind to extracellular matrix
proteins like fibronectin, collagen I, collagen IV, or lam-
inin I compared to SK [16]. Therefore, we hypothesized
that in the absence of TGFBI, the integrins could bind
to the ECM providing attachment sites for cells inducing
more invasion, or acting as a physical drug barrier,
restricting drug transport and limiting their efficacy. The
intratumoral diffusion and physical masking of HER re-
ceptors by ECM proteins have also been described as a
mechanism that can affect the therapeutic efficacy of
some drugs including trastuzumab [57].
Finally, we correlated the previous in vitro results in hu-
man samples treated with neoadjuvant anthracycline-
taxane-based chemotherapy plus trastuzumab. In our pre-
liminary study, a higher TGFBI methylation level after
treatment was observed in patients who developed treat-
ment resistance. These results are in accordance with
other studies which demonstrated an association between
TGFBI hypermethylation and poor prognosis in prostate
and lung cancer [41]. Moreover, decreased TGFBI expres-
sion was identified in advanced stages of BC and NSCLC
tumors [40, 58]. Due to the small size of the patient cohort
and the retrospective design, the role of TGFBI methyla-
tion as a biomarker requires further validation in a larger
and independent cohort. Nevertheless, the present study
brings to light for the first time that TGFBI methylation
has a significant discriminative value between pre- and
post-treatment samples, as demonstrated by ROC curve
analyses. Interestingly, the TGFBI promoter methylation
analysis in responder patients showed similar methylation
levels with pre-treatment samples of non-responders. This
observation suggests a possible role of TGFBI as a moni-
toring biomarker for trastuzumab response in patients
with HER2+ BC.
Although no significant association was found between
TGFBI methylation before and after treatment and pa-
tients’ clinical-histopathologic characteristics, a high num-
ber ER-positive patients were observed. In this sense,
previous studies have shown that there is crosstalk be-
tween ER and HER2 pathways and it affects the response
to treatment [59]. In addition, although the type of surgery
is not associated with a higher TGFBI methylation level in
post-treatment samples, 73% of our patients were treated
with mastectomy versus 27% with lumpectomy, probably
due to the high prevalence of stage III. The low histo-
logical grade and high clinical stage to treatment were
probably due to most of the patients having non-operable
cancers including inflammatory tumors. Currently, neoad-
juvant treatment is generally used for operable HER2+ BC
thanks to an improvement in the efficacy of the drugs
used for treatment [60]. At the time our cohort was
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treated, none of these drugs were yet available. That said,
trastuzumab remains the gold standard treatment for
HER2+ BC.
Conclusions
The results obtained in this study have provided an
overview of the DNA methylation pattern in HER2+-
resistant BC. TGFBI promoter hypermethylation could
be a potential methylation monitoring biomarker for
trastuzumab response. In addition, once the resistance
is developed, demethylation of TGFBI with com-
pounds that inhibit DNA methyltransferases could
contribute to the sensitization of breast cancer cells
to the trastuzumab treatment. However, further stud-
ies are required to identify the specific role TGFBI
plays in trastuzumab resistance in the neoadjuvant
settings to definitively show TGFBI as a clinical rele-
vant biomarker. Future studies based on TGFBI pro-
moter methylation analyses in circulating DNA during
neoadjuvant treatment could be a potential strategy
with which to confirm our findings.
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Additional file 1: Additional methods. (DOCX 30 kb)
Additional file 2: Figure S1. DNA methylation-associated silencing of
CXCL2 and SLC38A1 comparing the trastuzumab-resistant (AUTR) and
-sensitive (AU) AU565 cell model. (A) Expression levels of CXCL2 and
SLC38A1 in the unmethylated (AU) and methylated (AUTR) models deter-
mined by qRT-PCR. (B) Restored expression of CXCL2 and SLC38A1 after
DNA demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) in the AUTR
methylated cell line by qRT-PCR. (C) DNA methylation levels of CXCL2 and
SLC38A1 in AU and AUTR cell lines by methylation-specific polymerase
chain reaction (MSP) analysis. (D) Protein expression of CXCL2 and
SLC38A1 in AU and AUTR cells before and after 5-aza-dC treatment by
Western blot. In MSP, the presence of visible polymerase chain reaction
products in lanes marked U indicate unmethylated sequences; the pres-
ence of products in lanes marked M indicate methylated sequences. In
vitro methylated DNA (IVD) was used as a positive control for methylated
sequences. DNA from normal lymphocytes (NL) was used as a negative
control for methylated sequences. Results shown are representative of
those obtained from three independent experiments and b- actin was
used as a control. Values from pyrosequencing and qRT-PCR were deter-
mined from triplicates and are expressed as the mean ± SEM. Significance
of Mann-Whitney U test, **p < 0.01; *p < 0.05. (PDF 235 kb)
Additional file 3: Figure S2. Cell viability determined by MTT assays
upon trastuzumab treatment for 5 days. (A) TGFBI depletion in SK cells,
(B) TGFBI overexpression in SKTR cells (TGFBI) and (C) TGFBI-mutagenesis
in SKTR cells (TGFBImut). The continuous line represents the fitted dose-
response curve while discontinuous lines indicate the simultaneous 95%
confidence interval (CIs) for the continuous line with the same color.
ANOVA using a Tukey HSD post hoc test, **P < 0.01; *P < 0.05 indicate
levels of statistical significance. (PDF 397 kb)
Additional file 4: Figure S3. Calibration curve for the reliability of
TGFBI to predict trastuzumab resistance. Calibration was assessed using
the Hosmer-Lemeshow test and graphically using a calibration plot. The
observed frequency was calculated for each group. Predicted probability
refers to the predicted probabilities generated by the model. Patients
were grouped according to deciles of the predicted probabilities.
Grouped patients refers to patients grouped at each decile of predicted
probabilities generated by the model. A LOWESS regression was fit to all
data points (blue line). (PDF 119 kb)
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